{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:57Z","timestamp":1785510717816,"version":"3.56.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Nationwide Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In pediatric inflammatory bowel disease (IBD), the optimal timing to begin therapeutic drug monitoring (TDM) of infliximab (IFX) is unclear. We hypothesized that TDM during induction of IFX improves clinical outcomes in children with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study utilized data from an internal database at Nationwide Children\u2019s Hospital between January 1, 2020, and December 31, 2023. Pediatric IBD patients receiving IFX with induction-phase TDM (I-TDM) at Week 6 were compared to those with maintenance-phase TDM (M-TDM) at Week 14. Propensity score matching (PSM) was used for sex, disease, and age at IFX start. The primary outcome was time to clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 68 patients were matched from each group. The I-TDM group experienced a shorter median time to clinical remission (140\u2009days [95% CI: 108, 167]) compared to the M-TDM group (203\u2009days [95% CI: 167, 232]; P\u2009=\u2009.006). When adjusting for baseline variations, I-TDM remained independently associated with accelerated clinical remission (aHR\u2009=\u20091.68, 95% CI: 1.10, 2.55; P\u2009=\u2009.016). While time to therapeutic maintenance IFX levels was similar, post hoc analysis showed that 75% of patients in the I-TDM group achieved target levels in 134\u2009days (95% CI: 114, 182) versus 183\u2009days (95% CI: 153, 224) in the M-TDM group. There were no significant differences in long-term complications between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Induction-phase TDM before the third infusion shortens the time to clinical remission, allowing for more prompt dose adjustments and improving patient outcomes. This approach warrants consideration in clinical practice for children with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag080","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:42:29Z","timestamp":1784288549000},"source":"Crossref","is-referenced-by-count":0,"title":["Induction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-6294","authenticated-orcid":false,"given":"Nicholas","family":"Iovino","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R","family":"Paglinco","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, St. Christopher\u2019s Hospital for Children , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-0718","authenticated-orcid":false,"given":"Mahmoud","family":"Abdel-Rasoul","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University , Columbus, OH,","place":["United States"]},{"name":"Biostatistics Resource, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"McNicol","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Boyle","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]},{"name":"Department of Pediatrics, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary K","family":"Michel","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]},{"name":"Department of Pediatrics, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-7555","authenticated-orcid":false,"given":"Ross M","family":"Maltz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]},{"name":"Department of Pediatrics, The Ohio State University Wexner Medical Center , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026073110415223800_otag080-B1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/gut.34.7.939","article-title":"Growth and clinical course of children with crohn\u2019s disease","volume":"34","author":"Griffiths","year":"1993","journal-title":"Gut"},{"key":"2026073110415223800_otag080-B2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ecco-jcc\/jjz106","article-title":"Phenotypic variation in paediatric inflammatory bowel disease by age: a multicentre prospective inception cohort study of the Canadian Children IBD Network","volume":"14","author":"Dhaliwal","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B3","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/ecco-jcc\/jjae087","article-title":"Considerations in paediatric and adolescent inflammatory bowel disease","volume":"18","author":"Vuijk","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2008.06.079","article-title":"Natural history of pediatric Crohn\u2019s disease: a population-based cohort study","volume":"135","author":"Vernier\u2013Massouille","year":"2008","journal-title":"Gastroenterology"},{"key":"2026073110415223800_otag080-B5","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1016\/j.crohns.2013.03.007","article-title":"Presenting features and disease course of pediatric ulcerative colitis","volume":"7","author":"Aloi","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5009\/gnl20337","article-title":"Clinical characteristics and long-term outcomes of pediatric ulcerative colitis: a single-center experience in Korea","volume":"16","author":"Jang","year":"2022","journal-title":"Gut Liver"},{"key":"2026073110415223800_otag080-B7","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/ajg.2013.248","article-title":"Diagnostic delay in Crohn\u2019s disease is associated with a complicated disease course and increased operation rate","volume":"108","author":"Schoepfer","year":"2013","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"2026073110415223800_otag080-B8","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/jcag\/gwad016","article-title":"The 2023 impact of inflammatory bowel disease in Canada: special populations\u2014children and adolescents with IBD","volume":"6(Supplement_2)","author":"El-Matary","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026073110415223800_otag080-B9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"Van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care\u2014an evidence-based guideline from European Crohn\u2019s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","article-title":"Management of paediatric ulcerative colitis, part 2: acute severe colitis\u2014an evidence-based consensus guideline from the European Crohn\u2019s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B15","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn\u2019s disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"The Lancet"},{"key":"2026073110415223800_otag080-B16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/jpn3.70160","article-title":"Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease","volume":"81","author":"Davidson","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2026073110415223800_otag080-B18","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.3390\/jcm12206577","article-title":"A review of therapeutic drug monitoring in patients with inflammatory bowel disease receiving combination therapy","volume":"12","author":"Patel","year":"2023","journal-title":"JCM"},{"key":"2026073110415223800_otag080-B19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ajg.2017.21","article-title":"Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy","volume":"112","author":"Papamichael","year":"2017","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"2026073110415223800_otag080-B20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPG.0000000000001029","article-title":"Practical use of infliximab concentration monitoring in pediatric Crohn disease","volume":"62","author":"Minar","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"2026073110415223800_otag080-B23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ecco-jcc\/jjw007","article-title":"Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease","volume":"10","author":"Moore","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026073110415223800_otag080-B24","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026073110415223800_otag080-B25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.14309\/ajg.0000000000002096","article-title":"Higher postinduction infliximab concentrations are associated with favorable clinical outcomes in pediatric Crohn\u2019s disease: a post hoc analysis of the REACH trial","volume":"118","author":"Cheifetz","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026073110415223800_otag080-B26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"The Lancet"},{"key":"2026073110415223800_otag080-B27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"2026073110415223800_otag080-B28","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026073110415223800_otag080-B29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cgh.2017.11.046","article-title":"Mucosal healing and long-term outcomes of patients with inflammatory bowel diseases receiving clinic-based vs trough concentration-based dosing of infliximab","volume":"16","author":"Pouillon","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026073110415223800_otag080-B30","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/jpn3.70158","article-title":"North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"81","author":"Felipez","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B31","year":"2022"},{"key":"2026073110415223800_otag080-B32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MPG.0000000000002051","article-title":"Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases","volume":"67","author":"Ungar","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","article-title":"Development of infliximab target concentrations during induction in pediatric Crohn disease patients","volume":"69","author":"Clarkston","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B34","doi-asserted-by":"publisher","first-page":"17562848231222337","DOI":"10.1177\/17562848231222337","article-title":"Early infliximab trough levels in paediatric IBD patients predict sustained remission","volume":"17","author":"Bevers","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"2026073110415223800_otag080-B35","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026073110415223800_otag080-B36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ibd.21128","article-title":"Health-related quality of life of youth with inflammatory bowel disease: a comparison with published data using the PedsQL 4.0 generic core scales","volume":"16","author":"Kunz","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2026073110415223800_otag080-B37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MPG.0000000000000850","article-title":"School attendance in children with functional abdominal pain and inflammatory bowel diseases","volume":"61","author":"Assa","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/archdischild-2019-317765","article-title":"Children and young people with inflammatory bowel disease attend less school than their healthy peers","volume":"105","author":"Barnes","year":"2020","journal-title":"Arch Dis Child"},{"key":"2026073110415223800_otag080-B39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpeds.2022.04.014","article-title":"High impact of pediatric inflammatory bowel disease on caregivers\u2019 work productivity and daily activities: an international prospective study","volume":"246","author":"Klomberg","year":"2022","journal-title":"J Pediatr"},{"key":"2026073110415223800_otag080-B40","first-page":"1368","article-title":"Out-of-pocket cost burden in pediatric inflammatory bowel disease: a cross-sectional cohort analysis","volume":"21","author":"Sin","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026073110415223800_otag080-B41","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1097\/MIB.0000000000001268","article-title":"Indirect costs and family burden of pediatric Crohn\u2019s disease in the United States","volume":"23","author":"Kahn","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026073110415223800_otag080-B42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026073110415223800_otag080-B43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026073110415223800_otag080-B44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jcph.1732","article-title":"Increased induction infliximab clearance predicts early antidrug antibody detection","volume":"61","author":"Eser","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag080\/69556624\/otag080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag080\/69556624\/otag080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:42:04Z","timestamp":1785508924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag080\/8738162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag080","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag080"}}